Intervention

Abiraterone acetate

ClinicalTrials.gov intervention label

Explore related research

Search across original and mapped records

Search results distinguish clinical terminology from original registry names. Shared trial participation does not imply treatment or approval.

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 59 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials59
Recruiting7
Common conditions25
Lead sponsors shown15
Advertisement

Clinical trials

59 shown
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate CancerNCT07213674 · 2025-11-28
RECRUITING
A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology ClinicsNCT07406282 · 2025-07-22
RECRUITING
Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate CancerNCT06616597 · 2025-02-13
RECRUITING
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)NCT06136624 · 2023-12-31
RECRUITING
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)NCT06136650 · 2023-12-18
RECRUITING
Phase II Randomised Controlled Trial of Patient-specific Adaptive vs. Continuous Abiraterone or eNZalutamide in mCRPCNCT05393791 · 2022-11-10
RECRUITING
Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.NCT05422911 · 2022-08-31
RECRUITING
Hyperpolarized (HP) 13C Pyruvate Magnetic Resonance Imaging (MRI) for Response Monitoring to Neoadjuvant AbirateroneNCT06384222 · 2024-12-09
ACTIVE_NOT_RECRUITING
M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)NCT06421935 · 2024-08-07
ACTIVE_NOT_RECRUITING
Outcomes of Local Treatment for Oligometastatic Prostate Cancer Diagnosed Using PSMA PET Imaging: OLIGOMET StudyNCT06430411 · 2024-05-31
NOT_YET_RECRUITING
A Study to Learn About the Study Medicines Called Enzalutamide and Abiraterone in People With Metastatic Castration-resistant Prostate CancerNCT05968599 · 2023-07-24
COMPLETED
Enzalutamide vs. Abiraterone in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC)NCT05520138 · 2022-08-29
COMPLETED
Enhanced Systemic Combined With Local Treatment for Primary and Metastatic Lesions in Oligo-metastatic Prostate CancerNCT05212857 · 2022-04-01
UNKNOWN
The Study of Olaparib Combined With Abiraterone and Prednisone in mHSPC Patients With HRR Gene MutationNCT05167175 · 2022-03-01
UNKNOWN
ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate CancerNCT04662580 · 2021-05-03
ACTIVE_NOT_RECRUITING
Fluzoparib and Abiraterone in the preSurgery Treatment of Prostate Cancer: FAST TrialNCT05223582 · 2021-05-01
UNKNOWN
Neoadjuvant Therapy of Abiraterone Plus ADT for Intraductal Carcinoma of the ProstateNCT04736108 · 2021-05-01
UNKNOWN
Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)NCT04477512 · 2021-02-19
COMPLETED
PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)NCT04556617 · 2020-09-21
TERMINATED
Oral EPI-7386 in Patients with Castration-Resistant Prostate CancerNCT04421222 · 2020-06-23
TERMINATED
Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)NCT03834519 · 2019-05-02
COMPLETED
A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate CancerNCT03706365 · 2018-11-26
ACTIVE_NOT_RECRUITING
Study to Evaluate CCS1477 in Advanced TumoursNCT03568656 · 2018-07-23
COMPLETED
Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)NCT02903160 · 2017-01-13
COMPLETED
Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With mCRPCNCT02913196 · 2016-12-30
COMPLETED
Men With Metastatic Castrate-Resistant Prostate Cancer Treated With Either Sipuleucel-T (Provenge®), Abiraterone Acetate (Zytiga®) or Enzalutamide (Xtandi®) Undergoing Cardiopulmonary EXercise TestingNCT02353715 · 2015-07-07
COMPLETED
Cabazitaxel Versus the Switch to Alternative AR Targeted Therapy Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Primary Resistant Patients to Abiraterone or EnzalutamideNCT02379390 · 2015-06-17
TERMINATED
An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)NCT02257736 · 2014-11-26
ACTIVE_NOT_RECRUITING
Study of Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC), Chemo-Naive, Who Received a Prior Diethylstilbestrol TherapyNCT02217566 · 2014-09-23
COMPLETED
Sequencing Abiraterone and Enzalutamide in mCRPCNCT02125357 · 2014-09-01
COMPLETED
A Phase II Neoadjuvant Study of Enzalutamide, Abiraterone Acetate, Dutasteride and Degarelix in Men With Localized Prostate Cancer Pre-prostatectomyNCT02159690 · 2014-09-01
WITHDRAWN
RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistance (The RESTORE Study)NCT02090114 · 2014-08-25
COMPLETED
A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC)NCT02034552 · 2014-03-07
COMPLETED
Abiraterone, Radiotherapy and Short-Term Androgen Deprivation in Unfavorable Localized Prostate CancerNCT01717053 · 2014-01-17
COMPLETED
Abiraterone Race in Metastatic Castrate-resistant Prostate CancerNCT01940276 · 2013-10-01
COMPLETED
Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate CancerNCT01848067 · 2013-08-14
COMPLETED
Post-marketing Surveillance Study on the Safety and Effectiveness of Abiraterone Acetate Among Adult Filipino Male Patients With Advanced Metastatic Castration Resistant Prostate CancerNCT01692483 · 2013-07-01
WITHDRAWN
A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)NCT01715285 · 2013-02-12
COMPLETED
Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of ARN 509 in Combination With Abiraterone AcetateNCT01792687 · 2013-02-05
COMPLETED
A Multicenter Phase I/II Trial of Abiraterone Acetate + BEZ235 in Metastatic, Castration-Resistant Prostate CancerNCT01717898 · 2013-01-31
TERMINATED
3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical ProstatectomyNCT01751451 · 2012-12-18
COMPLETED
A Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based ChemotherapyNCT01695135 · 2012-08-09
COMPLETED
A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone AcetateNCT01517802 · 2012-03-28
COMPLETED
Cabazitaxel and Abiraterone Acetate in Patients With Metastatic Castrate-Resistant Prostate CancerNCT01511536 · 2012-03-01
COMPLETED
Abiraterone Acetate Combined With Dutasteride for Metastatic Castrate Resistant Prostate CancerNCT01393730 · 2011-09-01
COMPLETED
A Study of Abiraterone Acetate (JNJ-212082) and Prednisolone in Patients With Advanced Prostate CancerNCT01685983 · 2011-08-30
COMPLETED
Abiraterone Post Ketoconazole for Prostate CancerNCT01199146 · 2010-09-10
COMPLETED
A Drug-Drug Interaction Study of Abiraterone Acetate Plus Prednisone With Dextromethorphan and Theophylline in Patients With Metastatic Castration-Resistant Prostate CancerNCT01017939 · 2010-01-01
COMPLETED
A Study to Assess the Effect of Abiraterone Acetate in Male Participants With Mild or Moderate Hepatic Impairment Compared to Matched Control Participants With Normal Hepatic FunctionNCT02001571 · 2009-08-01
COMPLETED
A QT/QTc and Multi-Dose Pharmacokinetic Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate CancerNCT00910754 · 2009-05-01
COMPLETED
Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate CancerNCT00887198 · 2009-04-28
COMPLETED
Abiraterone Acetate in Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based ChemotherapyNCT00638690 · 2008-05-01
COMPLETED
An Observational Study of Continuous Oral Dosing of Abiraterone Acetate in Castration-Resistant Prostate Cancer Patients Evaluating Androgens and Steroid Metabolites in Bone Marrow PlasmaNCT00544440 · 2007-10-01
COMPLETED
An Efficacy and Safety Study of Abiraterone Acetate and Prednisone in Participants With Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based ChemotherapyNCT00485303 · 2007-06-01
COMPLETED
An Expanded Access Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer Who Have Completed Clinical Study COU-AA-001NCT01664728 · 2007-04-01
COMPLETED
An Safety and Efficacy Study of Abiraterone Acetate in Participants With Advanced Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based ChemotherapyNCT00474383 · 2006-11-01
COMPLETED
Abiraterone Acetate Dose-Escalation Study in Hormone Refractory Prostate CancerNCT00473746 · 2006-06-01
COMPLETED
A Safety and Efficacy Study of Abiraterone Acetate in Participants With Prostate Cancer Who Have Failed Hormone TherapyNCT00473512 · 2005-11-01
COMPLETED
A Study of Abiraterone Acetate Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate CancerNCT01834209
NO_LONGER_AVAILABLE

Common conditions

Trial status mix

COMPLETED35
RECRUITING7
ACTIVE_NOT_RECRUITING5
TERMINATED4
UNKNOWN4
WITHDRAWN2
NO_LONGER_AVAILABLE1
NOT_YET_RECRUITING1

Phase mix

PHASE232
PHASE117
PHASE311
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.